Limits...
The effects of arginase inhibitor on lung oxidative stress and inflammation caused by pneumoperitoneum in rats.

Cho JS, Oh YJ, Kim OS, Na S - BMC Anesthesiol (2015)

Bottom Line: We found that plasma nitrite levels were lower in the PP group and higher in the PP-ABH group, compared with controls (P <0.01 and P <0.05, respectively).In the PP group, endothelial NOS activity was decreased and inducible NOS activity was increased compared with the PP-ABH and control groups.Pneumoperitoneum decreases NO bioavailability and increases the inflammation cytokines, resulting in organ injuries.

View Article: PubMed Central - PubMed

Affiliation: Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. chjs0214@yuhs.ac.

ABSTRACT

Background: Pneumoperitoneum-induced oxidative stress and organ injury are known to be associated with nitric oxide (NO) inactivation. Because arginase competes with NO synthase (NOS) for a common substrate, L-arginine, arginase inhibition may increase NO bioavailability. Therefore, we evaluated the ability of the arginase inhibitor, 2 (S)-amino-6-boronohexanoic acid (ABH), to attenuate pneumoperitoneum-induced decrease of NO bioavailability and lung injury.

Methods: Thirty rats were randomly divided into the following groups: 1) the PP-ABH group received a subcutaneous injection of ABH (5 mg/kg) 1 h before induction of pneumoperitoneum (insufflation to intraperitoneal pressure of 15 mmHg for 60 min); 2) the PP group received saline by subcutaneous injection 1 h before induction of pneumoperitoneum; and 3) the control group received saline by subcutaneous injection before a sham procedure with no gas insufflation. After desufflation, blood was collected to determine levels of plasma nitrite, NOS, inflammatory cytokines, and malondialdehyde, a marker of oxidative stress. Lung tissue was obtained for histological evaluation.

Results: We found that plasma nitrite levels were lower in the PP group and higher in the PP-ABH group, compared with controls (P <0.01 and P <0.05, respectively). In the PP group, endothelial NOS activity was decreased and inducible NOS activity was increased compared with the PP-ABH and control groups. Malondialdehyde levels increased 3-fold in the PP group and 2-fold in the PP-ABH group compared with controls. Tumor necrosis factor-α, interleukin-6, and interleukin-1ß levels were elevated in the PP group compared to the control group, but the increase in cytokine production was attenuated or blocked in the PP-ABH group. Lung injury scores were 4.8-fold higher in the PP group and 2-fold higher in the PP-ABH group compared with controls (P <0.001 and P <0.01, respectively).

Discussion: Pneumoperitoneum decreases NO bioavailability and increases the inflammation cytokines, resulting in organ injuries. Inhibition of arginase activity could maintain NO bioavailability by attenuating pneumoperitoneum-induced changes in NOS activity. In addition, arginase inhibition attenuated the oxidative stress and inflammation and decreased the severity of lung injury caused by pneumoperitoneum.

Conclusions: By increasing NO bioavailability and suppressing oxidative stress and inflammation, pretreatment with an arginase inhibitor may protect against lung injury caused by pneumoperitoneum.

No MeSH data available.


Related in: MedlinePlus

Plasma nitrite levels. Plasma nitrite, a stable metabolite of NO, was decreased in the PP group but increased in the PP-ABH group compared to controls. *P <0.05, **P <0.01, ***P <0.001
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4587728&req=5

Fig2: Plasma nitrite levels. Plasma nitrite, a stable metabolite of NO, was decreased in the PP group but increased in the PP-ABH group compared to controls. *P <0.05, **P <0.01, ***P <0.001

Mentions: Level of plasma nitrite, a stable metabolite of NO, was significantly lower in the PP group compared with the PP-ABH and control groups (19 ± 6.1 μmol/L vs. 60 ± 1.3 μmol/L and 42 ± 9.0 μmol/L, respectively, P <0.001 and P <0.01, respectively) (Fig. 2). In addition, plasma nitrite level was higher in the PP-ABH group compared with the control group (P <0.05).Fig. 2


The effects of arginase inhibitor on lung oxidative stress and inflammation caused by pneumoperitoneum in rats.

Cho JS, Oh YJ, Kim OS, Na S - BMC Anesthesiol (2015)

Plasma nitrite levels. Plasma nitrite, a stable metabolite of NO, was decreased in the PP group but increased in the PP-ABH group compared to controls. *P <0.05, **P <0.01, ***P <0.001
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4587728&req=5

Fig2: Plasma nitrite levels. Plasma nitrite, a stable metabolite of NO, was decreased in the PP group but increased in the PP-ABH group compared to controls. *P <0.05, **P <0.01, ***P <0.001
Mentions: Level of plasma nitrite, a stable metabolite of NO, was significantly lower in the PP group compared with the PP-ABH and control groups (19 ± 6.1 μmol/L vs. 60 ± 1.3 μmol/L and 42 ± 9.0 μmol/L, respectively, P <0.001 and P <0.01, respectively) (Fig. 2). In addition, plasma nitrite level was higher in the PP-ABH group compared with the control group (P <0.05).Fig. 2

Bottom Line: We found that plasma nitrite levels were lower in the PP group and higher in the PP-ABH group, compared with controls (P <0.01 and P <0.05, respectively).In the PP group, endothelial NOS activity was decreased and inducible NOS activity was increased compared with the PP-ABH and control groups.Pneumoperitoneum decreases NO bioavailability and increases the inflammation cytokines, resulting in organ injuries.

View Article: PubMed Central - PubMed

Affiliation: Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. chjs0214@yuhs.ac.

ABSTRACT

Background: Pneumoperitoneum-induced oxidative stress and organ injury are known to be associated with nitric oxide (NO) inactivation. Because arginase competes with NO synthase (NOS) for a common substrate, L-arginine, arginase inhibition may increase NO bioavailability. Therefore, we evaluated the ability of the arginase inhibitor, 2 (S)-amino-6-boronohexanoic acid (ABH), to attenuate pneumoperitoneum-induced decrease of NO bioavailability and lung injury.

Methods: Thirty rats were randomly divided into the following groups: 1) the PP-ABH group received a subcutaneous injection of ABH (5 mg/kg) 1 h before induction of pneumoperitoneum (insufflation to intraperitoneal pressure of 15 mmHg for 60 min); 2) the PP group received saline by subcutaneous injection 1 h before induction of pneumoperitoneum; and 3) the control group received saline by subcutaneous injection before a sham procedure with no gas insufflation. After desufflation, blood was collected to determine levels of plasma nitrite, NOS, inflammatory cytokines, and malondialdehyde, a marker of oxidative stress. Lung tissue was obtained for histological evaluation.

Results: We found that plasma nitrite levels were lower in the PP group and higher in the PP-ABH group, compared with controls (P <0.01 and P <0.05, respectively). In the PP group, endothelial NOS activity was decreased and inducible NOS activity was increased compared with the PP-ABH and control groups. Malondialdehyde levels increased 3-fold in the PP group and 2-fold in the PP-ABH group compared with controls. Tumor necrosis factor-α, interleukin-6, and interleukin-1ß levels were elevated in the PP group compared to the control group, but the increase in cytokine production was attenuated or blocked in the PP-ABH group. Lung injury scores were 4.8-fold higher in the PP group and 2-fold higher in the PP-ABH group compared with controls (P <0.001 and P <0.01, respectively).

Discussion: Pneumoperitoneum decreases NO bioavailability and increases the inflammation cytokines, resulting in organ injuries. Inhibition of arginase activity could maintain NO bioavailability by attenuating pneumoperitoneum-induced changes in NOS activity. In addition, arginase inhibition attenuated the oxidative stress and inflammation and decreased the severity of lung injury caused by pneumoperitoneum.

Conclusions: By increasing NO bioavailability and suppressing oxidative stress and inflammation, pretreatment with an arginase inhibitor may protect against lung injury caused by pneumoperitoneum.

No MeSH data available.


Related in: MedlinePlus